Avangard: Fighting the Tide (April 16, 2015)

Avangard posted a 37% drop in revenues and a 49% drop in EBITDA for 2014. The key drivers for this were the negative effect of the UAH devaluation on sales (while average shell egg prices grew by 12% in UAH terms, in USD terms they fell by 24%) and the decrease in production capacity as a result of the annexation of Crimea and active military clashes in Eastern Ukraine (laying hens’ flock declined by 31% y/y to 18.6 mn as of end-December, which caused a 10% drop in production of shell eggs). The combination of the aforementioned factors with the declining prices of dry egg products and the conflict in Middle East, which affected Avangard’s export sales to the MENA region, resulted in a really bad 4Q2014: the company’s production of shell eggs dropped by 37% y/y, while 4Q2014 EBITDA amounted to just USD 24 mn, a 76% y/y drop compared to 4Q2013. On the positive site, the company’s export share in 2014 amounted to 37%, 8pp higher than in 2013, while Avangard recorded a five-fold increase in sales of its own packaged eggs brand ‘Kvochka’ (although it still comprised only 5% of egg sales). Thus, while the company now looks much “smaller” in terms of production volumes and sales, we are moderately positive on the future prospects of Avangard, reiterating our BUY recommendation with a new target price of USD 4.52 per GDR, or a 61% upside to the current price of USD 2.80. 

Refinancing of Avangard’s Eurobonds due in October 2015 imminent. While the company’s cash balance stood at a healthy USD 117 mn as of end-December, we estimate the company has to pay out around USD 46 mn in coupon and interest payments, as well as another USD 40 mn on maintenance capex in 2015. Considering an estimated cash from operations of USD 71 mn in 2015, Avangard won’t be able to repay its USD 200 mn Eurobonds as they become due. Therefore, under our base-case scenario, the company will refinance its Eurobonds by issuing new notes with prolonged maturity (an amortization scheme with 50% payable in 2018, and another 50% - in 2019 to decrease the pressure on any given year) and an increased coupon rate (10.5%), paying 20% of the principal in 2015 to attract bondholders to convert their old issue. 

The company has lost control of nearly 12% of its laying hens capacities due to the continuing conflict in Eastern Ukraine and occupation of the Crimean peninsula, and had to reduce poultry flock or close down poultry farms in adjacent areas. We expect the company’s production of shell eggs will drop by 14% to 5.4 bn pcs in 2015 as a result. However, we estimate that Avangard will be able to increase its laying hens population to about 22 mn by 2018 by increasing the utilization rate of existing facilities and restoring operation of its poultry farm in Kharkiv (not affected by the conflict in Eastern Ukraine).

The devaluation of the UAH to 24-25 per USD and lower production volumes should result in lower sales this year. We estimate Avangard’s revenue at USD 329 mn in 2015, with two-thirds of sales being generated by the shell egg segment and one-third—by the egg product segment. 

We estimate Avangard’s EBITDA at USD 112 mn in 2015 and USD 94 mn in 2016. EBITDA margin is likely to stay around 30-34% compared to 46% in 2013 as cost inflation catches up with domestic price increases, while global prices remain low. The company’s profitability will be positively affected by the cost benefits of the UAH devaluation on the egg product segment due to the 85% share of export sales, however this is not the case for the shell egg segment, where only 13% of the total sales volume is exported. 

We reiterate our BUY recommendation with a target price of 4.52, implying an upside of 61% to the current market price of USD 2.80 per GDR.

We derive our target GDR price from DCF analysis (50% weight) and relative valuation based on P/E and EV/EBITDA multiples (50% weight) compared with Ukrainian, Russian and global agro peers. Avangard trades at 5.0x 2015 earnings and 2.8x 2015 EV/EBITDA, implying a discount of 9% and 36%, respectively, to its closest peer Ovostar. On a 2015f P/E basis, we estimate that stock trades at discounts of 9% and 60% to Ukrainian and global peers, respectively, while on a EV/2015 EBITDA basis, we estimate that the stock trades at discounts of 39% and 56%, respectively. Our valuation suggests a target price of USD 4.52 per GDR, which implies an upside of 61%.

 

Disclaimer

Although the information in this report has been obtained from sources which Empire State Capital Partners believes to be reliable and was collected in good faith, we do not represent or warrant its accuracy, except with respect to information concerning Empire State Capital Partners, its subsidiaries and affiliates, either expressly or implied, and such information may be incomplete or condensed. Nor has the information and/or data been independently verified, and so is provided without further caveat regarding its reliability, suitability for commerce or specific purpose. 

This report does not constitute a prospectus and is not intended to provide the sole basis for an evaluation of the securities discussed herein. All estimates and opinions included in this report constitute our judgment as of the date of the report and may be subject to change without notice. Empire State Capital Partners or its affiliates may, from time to time, have a position or make a market in the securities mentioned in this report, or in derivative instruments based thereon, may solicit, perform or have performed investment banking, or other services (including acting as advisor, manager) for any company referred to in this report and may, to the extent permitted by law, have used the information herein contained, or the research or analysis upon which it is based, before its publication. Empire State Capital Partners will not be responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission. This report is confidential and is being submitted to select recipients only. It may not be reproduced (in whole or in part) without the prior written permission of Empire State Capital Partners.

Any recommendations, opinions, forecasts, estimates or views herein constitute a judgment as at the date of this report. This document has been produced independently of Empire State Capital Partners and the recommendations, forecasts, opinions, estimates, expectations, and views contained herein are entirely those of the research analyst(s). While all reasonable care has been taken to ensure that the facts presented herein are accurate and that the respective recommendations, forecasts, opinions, estimates, expectations, and views are fair and well considered, none of the research analyst(s), Empire State Capital Partners or any of its directors, managers or employees has verified the contents of this document and, accordingly, no research analyst, Empire State Capital Partners or any of its respective directors, managers or employees shall be in any way responsible for its contents.